Overview

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
Evaluate individual differences in the expression of opioid withdrawal symptoms in persons with opioid use disorder while they are completing a clinically-indicated medication taper.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Clonidine
Lofexidine
Morphine
Naloxone